StreetInsider.com News Articles

Quantum-Si to Provide a Business Update and Report Third Quarter 2026 Financial Results on November 5, 2026

Fri, 16 Oct 2026 08:00:00 -0400

BRANFORD, Conn., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics technology company redefining protein analysis through single-molecule detection, today announced that it will provide a business update and report financial results for the third quarter 2026 on Thursday, November 5, 2026. Jeff Hawkins, President and Chief Executive Officer, and Jeff Keyes, Chief Financial Officer, will host a conference call on the same day at 4:30 PM ET.

Individuals interested in listening to the conference call may do so by joining the live webcast on the Investors

Quantum-Si to Provide a Business Update and Report Third Quarter 2026 Financial Results on November 5, 2026

Fri, 16 Oct 2026 08:00:00 -0400

Individuals interested in listening to the conference call may do so by joining the live webcast on the Investors

Form 8-K Quantum-Si Inc For: Oct 14

Thu, 15 Oct 2026 09:16:00 -0400

si-local-file:///var/storage/secattach/20261015/27190976.html

Quantum-Si regains Nasdaq compliance after stock price recovery

Thu, 15 Oct 2026 09:00:09 -0400

Quantum-Si Incorporated (NASDAQ: QSI) announced it has received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC confirming the company has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Global Market under Listing Rule 5450(a)(1).

Nasdaq determined that the closing bid price of the company's common stock had been at or above $1.00 per share for at least 10 consecutive business days. Nasdaq advised the company that the matter is closed.

Quantum-Si Regains Compliance with Nasdaq Minimum Bid Price Requirement

Thu, 15 Oct 2026 09:00:00 -0400

BRANFORD, Conn., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI,” or the “Company”), a proteomics company redefining protein analysis through single-molecule protein sequencing, today announced that it has received written notice from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Global Market under Listing Rule 5450(a)(1). Nasdaq determined that the closing bid price of the Company’s common stock had been at or above $1.00 per share

Quantum-Si Regains Compliance with Nasdaq Minimum Bid Price Requirement

Thu, 15 Oct 2026 09:00:00 -0400

H.C. Wainwright Reiterates Buy Rating on Quantum-SI Inc. (QSI)

Fri, 09 Oct 2026 06:49:01 -0400

H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating and $4.00 price target on Quantum-SI Inc. (NASDAQ: QSI).

The analyst commented: "On October 8, Quantum-Si announced detection of 19 amino acids in its Proteus development program, advancing beyond the developmental 18-amino-acid kit used for the interim World HUPO 2026 results released on September 28 (see our note). Management remains confident in demonstrating detection of all 20 amino acids by year-end 2026, citing the pace of progress in its recognizer program. We view the update as incrementally encouraging, but we distinguish detection capability from routine sequencing on an integrated instrument. We believe

Form 8-K Quantum-Si Inc For: Oct 08

Thu, 08 Oct 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20261008/27167118.html

Quantum-Si reports detection of 19 amino acids in Proteus program

Thu, 08 Oct 2026 16:05:44 -0400

Quantum-Si Incorporated (Nasdaq: QSI) announced it has demonstrated detection of 19 amino acids in its Proteus development program and is working to deploy that capability into a developmental sequencing kit for use on integrated Proteus instruments.

The company said the milestone builds on interim Proteus results presented at the 2026 World HUPO Congress, where Quantum-Si showed sequencing performance improvements using a developmental kit that detects 18 amino acids.

"Demonstrating detection of 19 amino acids is an important step toward our goal of detecting all 20 amino acids by the end of 2026," said Jeff Hawkins, President and Chief Executive Officer of Quantum-Si.

Quantum-Si Demonstrates Detection of 19 Amino Acids in Proteus™ Development Program

Thu, 08 Oct 2026 16:05:00 -0400

Company is working to deploy 19-amino-acid detection into a developmental sequencing kit and remains confident in demonstrating detection of all 20 amino acids by year-end 2026

BRANFORD, Conn., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics company redefining protein analysis through single-molecule protein sequencing, today announced that it has demonstrated detection of 19 amino acids in its Proteus™ development program and is now working to deploy that capability into a developmental sequencing kit for routine use on integrated Proteus instruments. Building on the interim Proteus results presented at the 2026

Quantum-Si Demonstrates Detection of 19 Amino Acids in Proteus™ Development Program

Thu, 08 Oct 2026 16:05:00 -0400

Company is working to deploy 19-amino-acid detection into a developmental sequencing kit and remains confident in demonstrating detection of all 20 amino acids by year-end 2026

Increasing unusual call option volume: QSI SYF FE HBAN WU PACB ACN SEV INSW JBS FICO

Thu, 01 Oct 2026 10:41:32 -0400

Increasing unusual call option volume: QSI SYF FE HBAN WU PACB ACN SEV INSW JBS FICO

Increasing unusual option volume: UAA PACB FNGR DC MRP KOD COUR QSI GLAS OHI

Wed, 30 Sep 2026 10:16:45 -0400

Increasing unusual option volume: UAA PACB FNGR DC MRP KOD COUR QSI GLAS OHI

H.C. Wainwright Reiterates Buy Rating on Quantum-SI Inc. (QSI)

Tue, 29 Sep 2026 06:50:47 -0400

H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating and $4.00 price target on Quantum-SI Inc. (NASDAQ: QSI).

The analyst commented: "This morning, MediciNova announced topline results from the Phase 2 NATG-202 study evaluating tipelukast (MN-001) for the treatment of hypertriglyceridemia (HTG) and nonalcoholic fatty liver disease (NAFLD) associated with type 2 diabetes (T2D). As a reminder, NATG-202 was a multi-center (U.S.), randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of tipelukast in 40 T2D patients with HTG and NAFLD (NCT05464784). Participants (FibroScan score ≥ 248 dB/m, HbA1c >6.5 and ≤10% at screening, oral anti-diabetic therapy for ≥3 months, fasting

Form 8-K Quantum-Si Inc For: Sep 28

Tue, 29 Sep 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260929/27116716.html

Quantum-Si Presents Interim Proteus™ Data at World HUPO 2026 Demonstrating a Significant Step Change in Performance Compared to Platinum® Pro

Mon, 28 Sep 2026 20:15:00 -0400

All measurable sequencing metrics show profound improvement over Platinum Pro

BRANFORD, Conn., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics company redefining protein analysis through single-molecule protein sequencing, today announced interim development results comparing its next-generation Proteus™ platform with its commercially available Platinum^® Pro instrument. Using a developmental sequencing kit that detects 18 amino acids, Proteus significantly outperformed Platinum Pro across every key measure, from sequencing scale and accuracy to peptide identification and protein sequence coverage, even though the Proteus instrument, consumable, loading protocol and analysis software are still in

Quantum-Si Presents Interim Proteus™ Data at World HUPO 2026 Demonstrating a Significant Step Change in Performance Compared to Platinum® Pro

Mon, 28 Sep 2026 20:15:00 -0400

All measurable sequencing metrics show profound improvement over Platinum Pro

Form 4 Quantum-Si Inc For: Sep 21 Filed by: Hawkins Jeffrey Alan

Wed, 23 Sep 2026 19:52:00 -0400

si-local-file:///var/storage/secattach/20260923/27097685.html

Form 4 Quantum-Si Inc For: Sep 21 Filed by: Keyes Jeffry R.

Wed, 23 Sep 2026 19:46:00 -0400

si-local-file:///var/storage/secattach/20260923/27097682.html

Form 4 Quantum-Si Inc For: Sep 21 Filed by: LaPointe Christian

Wed, 23 Sep 2026 19:41:00 -0400

si-local-file:///var/storage/secattach/20260923/27097680.html

Form 144 Quantum-Si Inc Filed by: Hawkins Jeffrey Alan

Wed, 23 Sep 2026 19:33:00 -0400

si-local-file:///var/storage/secattach/20260923/27097674.html

Form 144 Quantum-Si Inc Filed by: LaPointe Christian

Wed, 23 Sep 2026 19:30:00 -0400

si-local-file:///var/storage/secattach/20260923/27097669.html

Form 144 Quantum-Si Inc Filed by: Keyes Jeffry R.

Wed, 23 Sep 2026 19:28:00 -0400

si-local-file:///var/storage/secattach/20260923/27097667.html

Quantum-Si detects 18 amino acids using Proteus sequencing kit

Tue, 15 Sep 2026 07:01:20 -0400

Quantum-Si Incorporated (Nasdaq: QSI) announced it has demonstrated detection of 18 amino acids using a developmental sequencing kit run on its integrated Proteus™ instruments, according to a press release dated Sept. 15, 2026.

The company said it continues to expect to demonstrate detection of all 20 amino acids by the end of 2026. Jeff Hawkins, President and Chief Executive Officer, said the result increases the company's confidence in achieving that goal.

"Demonstrating detection of 18 amino acids and incorporating that capability into a developmental sequencing kit that has been successfully run on integrated Proteus instruments is a significant milestone for our company,"

Quantum-Si Announces Detection of 18 Amino Acids Using a Developmental Sequencing Kit on Proteus™

Tue, 15 Sep 2026 07:00:00 -0400

Milestone continues the progress towards detection of all 20 amino acids by end of 2026

BRANFORD, Conn., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics company redefining protein analysis through single-molecule protein sequencing, today announced that it has demonstrated sequencing with detection of 18 amino acids using a developmental kit run on integrated Proteus™ instruments. The Company continues to expect to demonstrate detection of all 20 amino acids in 2026.

“Demonstrating detection of 18 amino acids and incorporating that capability into a developmental sequencing kit that has been successfully